BioWorld MedTech

May 14, 2015

Financings: Glaukos files IPO, could be first public company in MIGS space

The latest development in the minimally invasive glaucoma surgical (MIGS) space comes from Glaukos (Laguna Hills, California) as the company has reportedly filed for an initial public offering (IPO) to raise $86 million. Read More

HRS annual Meeting : EP; HRS in danger of losing seat at the AMA RUC table

PLAC build-up: Cardio diagnostics broadening

Take a moment to complete critical reader survey

ResMed Fails to Hold SERVE: ResMed stock down after SERVE-HF misses its primary endpoint

Agreements/contracts: Abbott, GE Healthcare to integrate electrogram data

World in Review: W.L. Gore registers Excluder endoprosthesis in Australia

Patent Watch: USPTO issues patent allowance for Rosetta Cancer Origin Test

Briefly Noted

Product briefs

People in Places

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Virtual IPO word with stock graph and arrow

Parabilis takes top spot, pricing largest biopharma IPO at $670M

BioWorld

Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...